ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v18i4.2247ppharm-2053Research ArticleКРАТКИЕ СООБЩЕНИЯSHORT REPORTРезолюция по итогам Экспертного совета «Современные возможности выбора ферментной заместительной терапии синдрома Хантера»Resolution on the results of the Expert council «Modern options of enzyme replacement therapy in Hunter syndrome management»РедакционнаястатьяEditorialArticle202117102021184324326Copyright © Редакционная с., 20212021Редакционная с.Editorial a.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2053
9 июня 2021 г. в Москве при поддержке компании «Такеда» состоялся совет экспертов на тему «Современные возможности выбора ферментной заместительной терапии синдрома Хантера».
.
ReferencesNeufeld Е, Muenzer J. The mucopolysaccharidosis. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, eds. 8th ed. New York, NY: McGraw-Hill; 2001. pp. 3421-3452.Neufeld Е, Muenzer J. The mucopolysaccharidosis. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, eds. 8th ed. New York, NY: McGraw-Hill; 2001. pp. 3421-3452.Scarpa М, Almassy Z, Beck М, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of а rare disease. Orphanet J Rare Dis. 2011;6:72-77. doi: 10.1186/1750-1172-6-72Scarpa М, Almassy Z, Beck М, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of а rare disease. Orphanet J Rare Dis. 2011;6:72-77. doi: 10.1186/1750-1172-6-72Muenzer J, Jones SA, Tylki-Szymanska А, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from а global patient registry. Orphanet J Rare Dis. 2017;12(1):82. doi: 10.1186/s13023-017-0635-zMuenzer J, Jones SA, Tylki-Szymanska А, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from а global patient registry. Orphanet J Rare Dis. 2017;12(1):82. doi: 10.1186/s13023-017-0635-zMeikle PJ, Hopwood JJ, Clague АЕ, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254. doi: 10.1001/jama.281.3.249Meikle PJ, Hopwood JJ, Clague АЕ, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254. doi: 10.1001/jama.281.3.249Wraith JE, Scarpa М, Beck М, et al. Mucopolysaccharidosis type II (Hunter syndrome): а clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267-277. doi: 10.1007/s00431-007-0635-4Wraith JE, Scarpa М, Beck М, et al. Mucopolysaccharidosis type II (Hunter syndrome): а clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267-277. doi: 10.1007/s00431-007-0635-4Sampayo-Cordero М, Miguel-Huguet В, Pardo-Mateos А. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). А new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019;14(1):230. doi: 10.1186/s13023-019-1202-6Sampayo-Cordero М, Miguel-Huguet В, Pardo-Mateos А. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). А new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019;14(1):230. doi: 10.1186/s13023-019-1202-6Bradley L, Haddow Н, Palomaki G. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from а systematic evidence review. Genet Med. 2017;19(11):1187-1201. doi: 10.1038/gim.2017.30Bradley L, Haddow Н, Palomaki G. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from а systematic evidence review. Genet Med. 2017;19(11):1187-1201. doi: 10.1038/gim.2017.30Guffon N, Heron В, Chabrol В. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: а retrospective observational study. Orphanet J Rare Dis. 2015;10:43. doi: 10.1186/s13023-015-0259-0Guffon N, Heron В, Chabrol В. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: а retrospective observational study. Orphanet J Rare Dis. 2015;10:43. doi: 10.1186/s13023-015-0259-0Giugliani R, Federhen А, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589-604. doi: 10.1590/S1415-47572010005000093Giugliani R, Federhen А, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589-604. doi: 10.1590/S1415-47572010005000093
The authors declare that there are no conflicts of interest present.